Denis A. Dufresne

Partner
Practice Area: Corporate

Denis Dufresne has over 20 years of experience in representing public and private companies, investment funds and lending institutions, and high net worth individuals including athletes and entertainers on complex business transactions and personal matters. Mr. Dufresne has extensive experience counseling clients in structuring, negotiating, documenting, and executing acquisitions and divestitures of businesses and assets (including licensing arrangements), leveraged buyouts, business combinations, equity and debt investments, debt restructuring, joint ventures and other individualized and commercial transactions.

Mr. Dufresne’s clients include founders, entrepreneurs, athletes, entertainers, emerging and established entities, independent members of public company boards, borrowers, lenders, placement agents and underwriters. His mergers and acquisitions transactional practice is across industry and includes a deep representation in the area of life sciences, where his background includes a broad experience in the full range of licensing and collaboration, structured M&A and other transactions common to this sector.

Education

J.D., St. John’s University School of Law

B.S., International Business, State University of New York at Plattsburgh (National Leadership Honor Society)

Admissions

New York

Prior Experience

Before joining MSF, Denis was with Lombardo Dufresne, LLP, a firm which he co-founded in 2006, and prior to that was counsel in the corporate finance group at Kaye Scholer LLP (1996 – 2006). Denis also served in-house as Deputy General Counsel for an oncology-focused pharmaceutical company (2010 – 2015).

Representative Matters

Represented Coeptis Therapeutics, Inc., a pharmaceutical company developing innovative cell therapy platforms for cancer, in negotiating and entering into a definitive merger agreement with Bull Horn Holdings Corp., (Nasdaq: BHSE), a special purpose acquisition company (SPAC), for a business combination that will result in Coeptis becoming a wholly-owned subsidiary of Bull Horn. Under the terms of the merger agreement, Coeptis isvalued at $175 million (subject to adjustments).

Represented Psycheceutical, Inc. a biotechnology company dedicated to the development and commercialization of psychedelic medicines, in a merger transaction in which Psycheceutical acquired Blue Water Ventures International, Inc. (OTCPK: BWVI). The transaction was structured as a merger transaction pursuant to which Psycheceutical became a wholly-owned subsidiary of BWVI (but was treated as the acquirer for financial accounting purposes).

Represented collective group of industrial adhesive company owners in a $100M sale to a private equity fund.

Represented four independent board members in connection with the separation from a public company board of directors.

Represented the owners of a bus refurbishing company in a $85M sale to a private equity fund.

Represented collective group of industrial adhesive company owners in a $100M sale to a private equity fund.

Represented a NYC-based pharmaceutical company in equity and debt transaction totaling over $500M, and over a dozen licensing and acquisition transactions.

Represented four independent board members in connection with the separation from a public company board of directors.